ACIU
AC Immune SA
Price Chart
Latest Quote
$2.25
-0.06 (-2.60%)
Current Price
| Previous Close | $2.31 |
| Open | $2.31 |
| Day High | $2.36 |
| Day Low | $2.03 |
| Volume | 469,024 |
Stock Information
Note: Financial values converted from CHF to USD
| Shares Outstanding | 99.43M |
| Total Debt | $4.94M |
| Cash Equivalents | $90.77M |
| Revenue | $21.09M |
| Net Income | $-51.98M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $223.71M |
| EPS (TTM) | $-0.54 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $152.46M |
| Sales | $21.09M |
| Income | $-51.98M |
| Book/sh | $0.43 |
| Cash/sh | $0.76 |
| Employees | 90 |
Financial Ratios
| Quick Ratio | 0.89 |
| Current Ratio | 0.93 |
| Debt/Eq | 11.66 |
Returns & Margins
| ROA | -16.04% |
| ROE | -78.53% |
| Gross Margin | -162.23% |
| Operating Margin | 7.89% |
| Profit Margin | -246.48% |
Ownership
| Insider Ownership | 38.09% |
| Institutional Ownership | 24.34% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 3.74 |
| P/S | 12.78 |
| P/B | 5.24 |
Analyst Data
| Recommendation | none |
| Target Price | $8.57 |
Technical Indicators
| SMA20 | $2.50 |
| SMA50 | $2.63 |
| SMA200 | $2.75 |
| RSI | 26.47 |
| ATR | 0.1060 |
| Shares Float | 39.18M |
| Short Float | 7.59% |
| Short Ratio | 21.42 |
| Volatility | 1.55 |
| Rel Volume | 2.25 |
Performance History
| Week | -9.64% |
| Month | -13.79% |
| Quarter | -0.88% |
| 6 Months | -25.74% |
| YTD | -33.04% |
| Year | -30.77% |
| 3 Years | -8.54% |
| 5 Years | -62.75% |
| 10 Years | -84.55% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $2.25 | 469,000 |
| 2026-10-26 | $2.31 | 397,900 |
| 2026-10-23 | $2.42 | 139,500 |
| 2026-10-22 | $2.50 | 73,000 |
| 2026-10-21 | $2.47 | 89,000 |
| 2026-10-20 | $2.49 | 140,100 |
| 2026-10-19 | $2.43 | 88,800 |
| 2026-10-16 | $2.39 | 126,800 |
| 2026-10-15 | $2.45 | 86,900 |
| 2026-10-14 | $2.40 | 209,700 |
| 2026-10-13 | $2.40 | 194,900 |
| 2026-10-12 | $2.45 | 148,500 |
| 2026-10-09 | $2.50 | 271,300 |
| 2026-10-08 | $2.55 | 231,900 |
| 2026-10-07 | $2.57 | 125,100 |
| 2026-10-06 | $2.52 | 277,800 |
| 2026-10-05 | $2.71 | 221,400 |
| 2026-10-02 | $2.72 | 320,200 |
| 2026-10-01 | $2.81 | 352,700 |
| 2026-09-30 | $2.62 | 199,600 |
| 2026-09-29 | $2.60 | 134,200 |
| 2026-09-28 | $2.61 | 188,900 |
About AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
đ° Latest News
No news articles available at the moment. Check back later for updates on ACIU.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $4,298,036 | $32,850,561 | $17,804,429 | $4,733,493 |
| Operating Revenue | $4,298,036 | $32,850,561 | $17,804,429 | $4,733,493 |
| Expenses | ||||
| Interest Expense | $229,758 | $159,988 | $211,714 | $427,037 |
| Total Expenses | $87,134,764 | $95,857,142 | $82,309,849 | $89,956,816 |
| Other Income Expense | $-3,919,116 | $-1,922,267 | $-1,764,685 | $472,748 |
| Net Non Operating Interest Income Expense | $2,013,689 | $3,684,546 | $1,044,135 | $-344,035 |
| Interest Expense Non Operating | $229,758 | $159,988 | $211,714 | $427,037 |
| Operating Expense | $87,134,764 | $95,857,142 | $82,309,849 | $89,956,816 |
| Other Operating Expenses | $3,285,176 | $5,449,231 | $2,612,744 | $5,851,006 |
| General And Administrative Expense | $14,016,432 | $13,754,195 | $12,722,089 | $11,526,386 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Net Interest Income | $2,013,689 | $3,684,546 | $1,044,135 | $-344,035 |
| Interest Income | $2,243,447 | $3,844,535 | $1,255,849 | $83,002 |
| Normalized Income | $-80,823,039 | $-59,489,036 | $-63,623,312 | $-85,521,539 |
| Net Income From Continuing And Discontinued Operation | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Total Operating Income As Reported | $-83,384,057 | $-63,006,580 | $-64,505,420 | $-85,223,323 |
| Net Income Common Stockholders | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Net Income | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Net Income Including Noncontrolling Interests | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Net Income Continuous Operations | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Pretax Income | $-84,742,155 | $-61,244,302 | $-65,225,969 | $-85,094,610 |
| Special Income Charges | $-547,329 | $0 | $0 | - |
| Interest Income Non Operating | $2,243,447 | $3,844,535 | $1,255,849 | $83,002 |
| Operating Income | $-82,836,728 | $-63,006,580 | $-64,505,420 | $-85,223,323 |
| Depreciation Amortization Depletion Income Statement | $1,945,123 | $1,386,968 | $1,288,328 | - |
| Depreciation And Amortization In Income Statement | $1,945,123 | $1,386,968 | $1,288,328 | - |
| Depreciation Income Statement | $1,945,123 | $1,386,968 | $1,288,328 | - |
| Per Share | ||||
| Diluted EPS | $-0.84 | $-0.61 | $-0.77 | $-1.02 |
| Basic EPS | $-0.84 | $-0.61 | $-0.77 | $-1.02 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $-163,393 | $-149,998 | $61,457 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-77,582,371 | $-56,561,331 | $-60,585,101 | $-82,302,631 |
| Total Unusual Items | $-3,919,116 | $-1,922,267 | $-1,764,685 | $472,748 |
| Total Unusual Items Excluding Goodwill | $-3,919,116 | $-1,922,267 | $-1,764,685 | $472,748 |
| Reconciled Depreciation | $3,010,911 | $2,600,715 | $2,664,469 | $2,837,690 |
| EBITDA (Bullshit earnings) | $-81,501,486 | $-58,483,599 | $-62,349,786 | $-81,829,884 |
| EBIT | $-84,512,397 | $-61,084,313 | $-65,014,255 | $-84,667,573 |
| Diluted Average Shares | $121,196,312 | $120,093,942 | $101,880,907 | $100,509,332 |
| Basic Average Shares | $121,196,312 | $120,093,942 | $101,880,907 | $100,509,332 |
| Diluted NI Availto Com Stockholders | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Tax Provision | $0 | $3,609 | $12,029 | $15,638 |
| Restructuring And Mergern Acquisition | $547,329 | $0 | $0 | - |
| Gain On Sale Of Security | $-3,371,787 | $-1,922,267 | $-1,764,685 | $472,748 |
| Research And Development | $67,888,033 | $75,266,748 | $65,686,688 | $72,579,423 |
| Selling General And Administration | $14,016,432 | $13,754,195 | $12,722,089 | $11,526,386 |
| Salaries And Wages | $14,016,432 | $13,754,195 | $12,722,089 | $11,526,386 |
Fetched: 2026-10-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-6,654,557 | $74,405,457 | $132,594,340 | $142,636,322 |
| Total Assets | $185,551,721 | $277,770,028 | $219,910,745 | $223,668,669 |
| Total Non Current Assets | $69,202,825 | $70,874,885 | $69,361,610 | $69,581,745 |
| Other Non Current Assets | $1,203 | - | - | - |
| Investmentin Financial Assets | $702,506 | $499,212 | $434,254 | $434,254 |
| Goodwill And Other Intangible Assets | $60,646,450 | $60,646,450 | $60,646,450 | $60,646,450 |
| Other Intangible Assets | $60,646,450 | $60,646,450 | $60,646,450 | $60,646,450 |
| Current Assets | $116,348,896 | $206,895,143 | $150,549,134 | $154,086,924 |
| Prepaid Assets | $4,778,001 | $5,174,965 | $7,743,201 | $5,663,351 |
| Receivables | $1,609,508 | $2,650,034 | $18,847,362 | $962,337 |
| Other Receivables | $529,285 | $1,495,230 | $350,050 | $639,954 |
| Taxes Receivable | $1,080,223 | $1,154,804 | $694,085 | $322,383 |
| Cash Cash Equivalents And Short Term Investments | $109,961,387 | $199,070,144 | $123,958,572 | $147,461,237 |
| Cash And Cash Equivalents | $32,232,260 | $43,635,948 | $94,422,057 | $37,995,453 |
| Accounts Receivable | - | $0 | $17,803,226 | $0 |
| Debt | ||||
| Total Debt | $5,462,463 | $6,528,251 | $4,206,614 | $3,369,381 |
| Long Term Debt And Capital Lease Obligation | $4,437,574 | $5,294,054 | $3,398,251 | $2,710,180 |
| Current Debt And Capital Lease Obligation | $1,024,888 | $1,234,197 | $808,363 | $659,201 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $131,559,828 | $142,718,121 | $26,669,955 | $20,385,897 |
| Total Non Current Liabilities Net Minority Interest | $17,651,658 | $21,418,003 | $10,339,103 | $6,575,165 |
| Non Current Deferred Liabilities | $2,813,632 | $5,485,318 | $0 | - |
| Current Liabilities | $113,908,170 | $121,300,118 | $16,330,851 | $13,810,733 |
| Current Deferred Liabilities | $100,691,680 | $102,315,623 | $166,003 | $706,114 |
| Payables And Accrued Expenses | $12,191,601 | $17,750,298 | $15,356,486 | $12,445,418 |
| Payables | $2,487,640 | $3,197,363 | $2,019,704 | $1,117,513 |
| Accounts Payable | $2,487,640 | $3,197,363 | $2,019,704 | $1,117,513 |
| Equity | ||||
| Common Stock Equity | $53,991,893 | $135,051,907 | $193,240,790 | $203,282,772 |
| Total Equity Gross Minority Interest | $53,991,893 | $135,051,907 | $193,240,790 | $203,282,772 |
| Stockholders Equity | $53,991,893 | $135,051,907 | $193,240,790 | $203,282,772 |
| Gains Losses Not Affecting Retained Earnings | $8,420 | $-6,015 | $-61,349 | $12,029 |
| Retained Earnings | $-528,107,449 | $-442,962,316 | $-380,359,917 | $-317,589,109 |
| Other | ||||
| Treasury Shares Number | $13,111,563 | $13,111,563 | $6,308,066 | $7,474,974 |
| Ordinary Shares Number | $122,387,836 | $120,785,721 | $119,327,122 | $100,588,667 |
| Share Issued | $135,499,398 | $133,897,284 | $125,635,188 | $108,063,641 |
| Tangible Book Value | $-6,654,557 | $74,405,457 | $132,594,340 | $142,636,322 |
| Invested Capital | $53,991,893 | $135,051,907 | $193,240,790 | $203,282,772 |
| Working Capital | $2,440,726 | $85,595,025 | $134,218,283 | $140,276,192 |
| Capital Lease Obligations | $5,462,463 | $6,528,251 | $4,206,614 | $3,369,381 |
| Total Capitalization | $53,991,893 | $135,051,907 | $193,240,790 | $203,282,772 |
| Foreign Currency Translation Adjustments | $8,420 | $-6,015 | $-61,349 | $12,029 |
| Treasury Stock | $262,237 | $262,237 | $126,307 | $149,162 |
| Additional Paid In Capital | $579,642,977 | $575,604,772 | $571,275,461 | $518,847,365 |
| Capital Stock | $2,710,180 | $2,677,701 | $2,512,901 | $2,161,648 |
| Common Stock | $2,710,180 | $2,677,701 | $2,512,901 | $2,161,648 |
| Employee Benefits | $10,400,452 | $10,638,631 | $6,940,852 | $3,864,984 |
| Non Current Deferred Revenue | $2,813,632 | $5,485,318 | $0 | - |
| Long Term Capital Lease Obligation | $4,437,574 | $5,294,054 | $3,398,251 | $2,710,180 |
| Current Deferred Revenue | $100,691,680 | $102,315,623 | $166,003 | $706,114 |
| Current Capital Lease Obligation | $1,024,888 | $1,234,197 | $808,363 | $659,201 |
| Current Accrued Expenses | $9,703,961 | $14,552,935 | $13,336,782 | $11,327,904 |
| Investments And Advances | $702,506 | $499,212 | $434,254 | $434,254 |
| Net PPE | $7,852,666 | $9,729,223 | $8,280,906 | $8,501,041 |
| Accumulated Depreciation | $-16,499,260 | $-14,998,015 | $-13,227,316 | $-11,238,888 |
| Gross PPE | $24,351,927 | $24,727,238 | $21,508,222 | $19,739,929 |
| Leases | $2,273,520 | $2,241,041 | $1,999,254 | $1,972,790 |
| Other Properties | $13,153,938 | $12,673,972 | $12,309,488 | $11,746,521 |
| Machinery Furniture Equipment | $3,548,616 | $3,412,686 | $3,054,216 | $2,759,500 |
| Buildings And Improvements | $5,375,853 | $6,399,538 | $4,145,265 | $3,257,509 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $77,729,127 | $155,434,195 | $29,536,515 | $109,465,784 |
| Construction In Progress | - | $0 | $0 | $3,609 |
Fetched: 2026-10-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-84,399,322 | $78,509,822 | $-73,629,573 | $-89,986,889 |
| Operating Activities | ||||
| Operating Cash Flow | $-83,316,694 | $79,202,705 | $-72,666,034 | $-88,496,470 |
| Cash Flow From Continuing Operating Activities | $-83,316,694 | $79,202,705 | $-72,666,034 | $-88,496,470 |
| Operating Gains Losses | $-1,883,774 | $-12,029 | $1,068,194 | $650,780 |
| Investing Activities | ||||
| Capital Expenditure | $-1,082,629 | $-692,882 | $-963,539 | $-1,490,419 |
| Investing Cash Flow | $76,435,987 | $-126,655,521 | $78,965,729 | $28,585,005 |
| Cash Flow From Continuing Investing Activities | $76,435,987 | $-126,655,521 | $78,965,729 | $28,585,005 |
| Net Other Investing Changes | $-204,497 | $-64,958 | - | $2,406 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $7,218 | $133,524 | $52,685,521 | $8,420 |
| Financing Cash Flow | $-1,226,979 | $-1,347,271 | $52,026,320 | $-1,619,131 |
| Cash Flow From Continuing Financing Activities | $-1,226,979 | $-1,347,271 | $52,026,320 | $-1,619,131 |
| Net Common Stock Issuance | $7,218 | $133,524 | $52,685,521 | $-1,203 |
| Common Stock Issuance | $7,218 | $133,524 | $52,685,521 | $8,420 |
| Net Other Financing Charges | - | $-659,201 | - | $-933,466 |
| Repurchase Of Capital Stock | - | - | - | $-9,623 |
| Other | ||||
| Repayment Of Debt | $-1,234,197 | $-821,595 | $-659,201 | $-684,462 |
| End Cash Position | $32,232,260 | $43,635,948 | $94,422,057 | $37,995,453 |
| Beginning Cash Position | $43,635,948 | $94,422,057 | $37,995,453 | $98,899,328 |
| Effect Of Exchange Rate Changes | $-3,296,003 | $-1,986,022 | $-1,899,412 | $626,722 |
| Changes In Cash | $-8,107,686 | $-48,800,087 | $58,326,016 | $-61,530,597 |
| Net Issuance Payments Of Debt | $-1,234,197 | $-821,595 | $-659,201 | $-684,462 |
| Net Long Term Debt Issuance | $-1,234,197 | $-821,595 | $-659,201 | $-684,462 |
| Long Term Debt Payments | $-1,234,197 | $-821,595 | $-659,201 | $-684,462 |
| Net Investment Purchase And Sale | $77,705,068 | $-125,897,680 | $79,929,269 | $30,073,018 |
| Net PPE Purchase And Sale | $-1,064,585 | $-692,882 | $-963,539 | $-1,490,419 |
| Sale Of PPE | $18,044 | $0 | $0 | $0 |
| Purchase Of PPE | $-1,082,629 | $-692,882 | $-963,539 | $-1,490,419 |
| Interest Received Cfo | $2,281,941 | $1,880,165 | $715,738 | $83,002 |
| Interest Paid Cfo | $-227,352 | $-155,177 | $-211,714 | $-574,996 |
| Change In Working Capital | $-8,149,788 | $129,330,816 | $-18,236,278 | $-10,143,027 |
| Change In Other Working Capital | $-4,295,630 | $107,634,938 | $-540,111 | $-156,380 |
| Change In Payables And Accrued Expense | $-5,356,606 | $2,826,864 | $2,293,970 | $-8,645,391 |
| Change In Accrued Expense | $-4,644,477 | $1,651,610 | $1,367,721 | $-7,354,657 |
| Change In Payable | $-712,129 | $1,175,254 | $926,249 | $-1,290,734 |
| Change In Prepaid Assets | $396,964 | $2,568,236 | $-2,102,705 | $-2,066,618 |
| Change In Receivables | $1,105,484 | $16,300,778 | $-17,887,431 | $725,361 |
| Changes In Account Receivables | $0 | $17,803,226 | $-17,803,226 | $0 |
| Other Non Cash Items | $1,105,484 | $226,149 | $1,320,807 | $-245,396 |
| Stock Based Compensation | $5,288,039 | $6,579,976 | $5,250,749 | $4,005,726 |
| Depreciation Amortization Depletion | $3,010,911 | $2,600,715 | $2,664,469 | $2,837,690 |
| Depreciation And Amortization | $3,010,911 | $2,600,715 | $2,664,469 | $2,837,690 |
| Depreciation | $3,010,911 | $2,600,715 | $2,664,469 | $2,837,690 |
| Pension And Employee Benefit Expense | $-1,865,730 | $-12,029 | $1,068,194 | $650,780 |
| Gain Loss On Sale Of PPE | $-18,044 | $0 | $0 | $0 |
| Net Income From Continuing Operations | $-84,742,155 | $-61,247,910 | $-65,237,998 | $-85,110,248 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
| Proceeds From Stock Option Exercised | - | - | - | $8,420 |
| Common Stock Payments | - | - | - | $-9,623 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
Fetched: 2026-10-15